OSUR – OraSure Technologies Inc.
OSUR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
5.4
Margin Of Safety %
Put/Call OI Ratio
0.02
EPS Next Q Diff
0.07
EPS Last/This Y
0.38
EPS This/Next Y
0.09
Price
3.07
Target Price
5
Analyst Recom
2
Performance Q
23.89
Upside
-775.8%
Beta
0.94
Ticker: OSUR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | OSUR | 3.2 | 0.03 | 0.00 | 5736 |
| 2026-03-10 | OSUR | 3.14 | 0.03 | 0.00 | 5736 |
| 2026-03-11 | OSUR | 3.19 | 0.03 | 0.00 | 5720 |
| 2026-03-12 | OSUR | 3.1 | 0.03 | 999.99 | 5763 |
| 2026-03-13 | OSUR | 3.09 | 0.03 | 999.99 | 5763 |
| 2026-03-17 | OSUR | 2.99 | 0.03 | 0.00 | 6323 |
| 2026-03-18 | OSUR | 2.91 | 0.03 | 0.04 | 6484 |
| 2026-03-19 | OSUR | 2.92 | 0.03 | 0.04 | 6484 |
| 2026-03-20 | OSUR | 2.95 | 0.03 | 0.00 | 7037 |
| 2026-03-23 | OSUR | 3.08 | 0.02 | 0.00 | 8711 |
| 2026-03-24 | OSUR | 3.07 | 0.02 | 5.25 | 8701 |
| 2026-03-25 | OSUR | 3.14 | 0.02 | 0.00 | 8720 |
| 2026-03-26 | OSUR | 3.06 | 0.02 | 999.99 | 8767 |
| 2026-03-27 | OSUR | 3 | 0.02 | 999.99 | 8777 |
| 2026-03-30 | OSUR | 2.92 | 0.02 | 1.00 | 8777 |
| 2026-03-31 | OSUR | 3.01 | 0.02 | 0.00 | 8778 |
| 2026-04-01 | OSUR | 3.05 | 0.02 | 0.00 | 8778 |
| 2026-04-02 | OSUR | 3.09 | 0.02 | 0.00 | 8778 |
| 2026-04-06 | OSUR | 3.07 | 0.02 | 0.00 | 8778 |
| 2026-04-07 | OSUR | 3.07 | 0.02 | 0.00 | 11413 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | OSUR | 3.20 | 9.1 | - | -0.56 |
| 2026-03-10 | OSUR | 3.13 | 9.1 | - | -0.56 |
| 2026-03-11 | OSUR | 3.19 | 9.1 | - | -0.56 |
| 2026-03-12 | OSUR | 3.10 | 9.1 | - | -0.56 |
| 2026-03-13 | OSUR | 2.98 | 9.1 | - | -0.56 |
| 2026-03-17 | OSUR | 2.99 | 9.1 | - | -0.56 |
| 2026-03-18 | OSUR | 2.91 | 9.1 | - | -0.56 |
| 2026-03-19 | OSUR | 2.92 | 9.1 | - | -0.56 |
| 2026-03-20 | OSUR | 2.95 | 9.1 | - | -0.56 |
| 2026-03-23 | OSUR | 3.08 | 9.1 | - | -0.56 |
| 2026-03-24 | OSUR | 3.06 | 9.1 | - | -0.56 |
| 2026-03-25 | OSUR | 3.14 | 9.1 | - | -0.56 |
| 2026-03-26 | OSUR | 3.06 | 9.1 | - | -0.56 |
| 2026-03-27 | OSUR | 3.00 | 9.1 | - | -0.56 |
| 2026-03-30 | OSUR | 2.93 | 9.1 | - | -0.56 |
| 2026-03-31 | OSUR | 3.01 | 9.1 | - | -0.56 |
| 2026-04-01 | OSUR | 3.04 | 9.1 | - | -0.56 |
| 2026-04-02 | OSUR | 3.08 | 9.1 | - | -0.56 |
| 2026-04-06 | OSUR | 3.08 | 9.1 | - | -0.56 |
| 2026-04-07 | OSUR | 3.07 | 9.1 | - | -0.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | OSUR | 0.05 | -3.58 | 5.94 |
| 2026-03-10 | OSUR | 0.05 | -3.58 | 5.94 |
| 2026-03-11 | OSUR | 0.05 | -3.58 | 5.65 |
| 2026-03-12 | OSUR | 0.05 | -3.58 | 5.87 |
| 2026-03-13 | OSUR | 0.05 | -3.58 | 5.87 |
| 2026-03-17 | OSUR | 1.18 | -3.61 | 5.87 |
| 2026-03-18 | OSUR | 1.18 | -3.61 | 5.87 |
| 2026-03-19 | OSUR | 1.18 | -3.61 | 5.87 |
| 2026-03-20 | OSUR | 1.18 | -3.61 | 5.87 |
| 2026-03-23 | OSUR | 1.18 | -3.61 | 5.87 |
| 2026-03-24 | OSUR | 2.89 | -3.61 | 5.87 |
| 2026-03-25 | OSUR | 2.89 | -3.61 | 5.40 |
| 2026-03-26 | OSUR | 2.89 | -3.61 | 5.40 |
| 2026-03-27 | OSUR | 2.89 | -3.61 | 5.40 |
| 2026-03-30 | OSUR | 2.89 | -3.62 | 5.40 |
| 2026-03-31 | OSUR | 2.89 | -3.62 | 5.40 |
| 2026-04-01 | OSUR | 2.89 | -3.62 | 5.40 |
| 2026-04-02 | OSUR | 2.89 | -3.62 | 5.40 |
| 2026-04-06 | OSUR | 2.89 | -3.57 | 5.40 |
| 2026-04-07 | OSUR | 2.89 | -3.57 | 5.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.21
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.14
Insider Transactions
2.89
Institutional Transactions
-3.57
Beta
0.94
Average Sales Estimate Current Quarter
27
Average Sales Estimate Next Quarter
29
Fair Value
Quality Score
36
Growth Score
30
Sentiment Score
54
Actual DrawDown %
77.4
Max Drawdown 5-Year %
-84.2
Target Price
5
P/E
Forward P/E
PEG
P/S
1.84
P/B
0.63
P/Free Cash Flow
EPS
-0.94
Average EPS Est. Cur. Y
-0.56
EPS Next Y. (Est.)
-0.47
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-59.76
Relative Volume
0.57
Return on Equity vs Sector %
-47.6
Return on Equity vs Industry %
-29.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
◆
OSUR
Healthcare
$3.06
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
53.3
Range 1M
43.3%
Sup Dist
0.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
15.4%
EPS NY
10.7%
52W%
56.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+63.4% upside
Upside
+63.4%
Quality
36
OraSure Technologies, Inc.Sector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 500
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
OSUR
Latest News
—
Caricamento notizie per OSUR…
stock quote shares OSUR – OraSure Technologies Inc. Stock Price stock today
news today OSUR – OraSure Technologies Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OSUR – OraSure Technologies Inc. yahoo finance google finance
stock history OSUR – OraSure Technologies Inc. invest stock market
stock prices OSUR premarket after hours
ticker OSUR fair value insiders trading